Mitochondrial respiratory chain and Krebs cycle enzyme function in human donor livers subjected to end-ischaemic hypothermic machine perfusion

Hamid Abudhaise1*, Jan-Willem Taanman2☯, Peter DeMuylder3☯, Barry Fuller1‡, Brian R. Davidson1‡

1 UCL Division of Surgery and Interventional Sciences, Royal Free Hospital, London, United Kingdom, 2 Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Royal Free Campus, London, United Kingdom, 3 Organ Recovery Systems, Zaventem, Belgium

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* hamid.abudhaise.11@ucl.ac.uk

Abstract

Introduction
Marginal human donor livers are highly susceptible to ischaemia reperfusion injury and mitochondrial dysfunction. Oxygenation during hypothermic machine perfusion (HMP) was proposed to protect the mitochondria but the mechanism is unclear. Additionally, the distribution and uptake of perfusate oxygen during HMP are unknown. This study aimed to examine the feasibility of mitochondrial function analysis during end-ischaemic HMP, assess potential mitochondrial viability biomarkers, and record oxygenation kinetics.

Methods
This was a randomised pilot study using human livers retrieved for transplant but not utilised. Livers (n = 38) were randomised at stage 1 into static cold storage (n = 6), hepatic artery HMP (n = 7), and non-oxygen supplemented portal vein HMP (n = 7) and at stage 2 into oxygen supplemented and non-oxygen supplemented portal vein HMP (n = 11 and 7, respectively). Mitochondrial parameters were compared between the groups and between low- and high-risk marginal livers based on donor history, organ steatosis and preservation period. The oxygen delivery efficiency was assessed in additional 6 livers using real-time measurements of perfusate and parenchymal oxygen.

Results
The change in mitochondrial respiratory chain (complex I, II, III, IV) and Krebs cycle enzyme activity (aconitase, citrate synthase) before and after 4-hour preservation was not different between groups in both study stages (p > 0.05). Low-risk livers that could have been used clinically (n = 8) had lower complex II-III activities after 4-hour perfusion, compared with high-risk livers (73 nmol/mg/min vs. 113 nmol/mg/min, p = 0.01). Parenchymal pO2 was...
also provided support in the form of research material and advice on using the perfusion machine and were involved in conceptualization and funding acquisition but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the ‘author contributions’ section.

**Competing interests:** I have read the journal’s policy and the authors of this manuscript have the following competing interests: Consumables and laboratory materials were partially funded by Organ Recovery Systems, https://www.organ-recovery.com. Author P. DeMuylder is employed by Organ Recovery Systems. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

consistently lower than perfusate pO$_2$ (p ≤ 0.001), stabilised in 28 minutes compared to 3 minutes in perfusate (p = 0.003), and decreased faster upon oxygen cessation (75 vs. 36 minutes, p = 0.003).

**Conclusions**

Actively oxygenated and air-equilibrated end-ischaemic HMP did not induce oxidative damage of aconitase, and respiratory chain complexes remained intact. Mitochondria likely respond to variable perfusate oxygen levels by adapting their respiratory function during end-ischaemic HMP. Complex II-III activities should be further investigated as viability biomarkers.

**Introduction**

The ongoing donor liver shortage prompted the relaxation of liver acceptance criteria and increased utilisation of high-risk donor or “marginal” livers. Marginal livers are obtained from elderly donors and those with multiple co-morbidities, donation after cardiac death (DCD), steatotic grafts, and livers with prolonged preservation times. These livers are highly susceptible to ischaemia reperfusion injury (IRI) and post-transplant complications [1–13]. New preservation methods were required to improve the outcome and utilisation of these high-risk donor organs.

Mitochondria have a crucial role in organ recovery following transplantation by restoring energy and producing adenosine triphosphate (ATP) via oxidative phosphorylation [14]. Conversely, the IRI process is greatly influenced by mitochondria through initiation of oxidative and inflammatory injuries which can lead to cell death and organ failure [8, 15–19]. Oxygen deprivation during ischaemia interrupts mitochondrial oxidative phosphorylation and results in highly reduced electron transport chain (ETC) enzymes [20, 21]. Furthermore, fumarate buildup during ischaemic preservation triggers the reverse activity of mitochondrial complex II and reduction of fumarate to succinate, the latter accumulating progressively and acting as an electron sink [15, 17, 18]. Accumulated succinate is rapidly oxidised upon reperfusion of the stored graft, triggering reverse electron transport (RET) in complex I and causing a burst of mitochondrial reactive oxygen species (ROS) [17, 20, 22, 23]. Prolonged ischaemia could also lead to irreversible and variable damage to ETC enzymes [24–27], but this aspect has not been illustrated in the human liver.

Dynamic organ preservation methods (normothermic and hypothermic machine perfusion) are increasingly advocated for resuscitation and selection of marginal livers. Hypothermic machine perfusion (HMP) has gained a lot of interest recently and clinical observational studies confirmed the safety of end-ischaemic “post-SCS” oxygenated and air-equilibrated HMP. Moreover, end-ischaemic HMP reduced biliary complications and attenuated IRI in marginal livers [28–33]. However, static cold storage (SCS) remains standard practice for liver preservation [34] and there are no clinically validated parameters of liver transplantability in end-ischaemic HMP. Importantly, the exact mechanism of protection in end-ischaemic HMP is not clearly defined.

The protective effect of hypothermic oxygenated machine perfusion (HOPE) was proposed to be secondary to downregulation of mitochondrial respiration and possibly lowered succinate accumulation, leading to mitochondrial stabilisation and an attenuated ROS burst upon reperfusion. These effects were dependent on active perfusate oxygenation [35–41], which was
shown to be safe despite earlier studies that warned against the risk of oxidative injury [42, 43]. However, the mechanism behind mitochondrial respiratory depression in HOPE is unknown, and oxygenated HMP in other experimental models increased the oxygen consumption and activated mitochondrial respiration [41, 44–47]. These studies differed in methodology and the measured outcomes, but the inconsistency in mitochondrial respiration results is unexplained. Additionally, air-equilibrated HMP decreased the inflammatory response with reperfusion but there is no evidence to link this to mitochondrial stabilisation [48–50]. Finally, the superiority of actively oxygenated or air-equilibrated perfusion is unknown and both modalities regenerated the depleted ATP and improved mitochondrial function compared with SCS [31, 37, 39, 40, 45, 47, 51–61]. Mitochondrial function has not been directly compared during oxygenated and air-equilibrated HMP in the human liver, and the interplay between perfusate oxygen distribution and local parenchymal uptake are unidentified in the human liver.

This study aimed to examine the feasibility of analysing the activity of mitochondrial ETC and Krebs cycle enzymes during end-ischaemic HMP, comparing arterial, oxygenated and non-oxygenated venous perfusion in a human liver model, and to identify markers of mitochondrial activity which could be evaluated as viability biomarkers. In addition, the delivery efficiency of oxygen to the human liver during end-ischaemic HMP was assessed.

Materials and methods

Participants

Ethical approval for the study was obtained from the North London Regional Ethics Committee 3 (reference no. 10/H0709/70) and confirmed with the National Health Service Blood and Transplant (NHSBT) Organ Donor Transplant committee. None of the organ donors was from a vulnerable population and a written informed consent was freely given by the next of kin.

The study involved 44 whole livers, including 38 livers used for mitochondrial assessment and 6 livers used for evaluation of oxygenation kinetics. Livers were procured for human transplantation by different organ procurement teams across the UK between February 2012 and June 2014. All livers had been retrieved using the standard clinical procurement protocols adopted by the UK National Organ Retrieval Service (NORS) [62]. The organs had been deemed unsuitable by the transplant team for clinical use and were subsequently offered for research. Livers were transported from the retrieval hospital to our research centre packed in ice and stored in University of Wisconsin (UW) solution as with routine clinical practice.

Donor variables including age, gender, heart-beating status, cause of death, weight, body mass index (BMI), alanine transaminase (ALT), bilirubin, UK donor liver index (DLI) [63], length of stay in the intensive care unit, warm ischaemic times (WIT), and graft steatosis grading were obtained from the Human Tissue Act-A (HTA-A) forms that accompany procured organs, local transplant coordinators records (manual search and verbally at the time of organ offer), and from the NHSBT Statistics and Clinical Studies Department (personal communication).

The 3 data sources were examined to establish the reasons for not utilising the livers for transplantation. In addition to the reported reasons for non-utilisation, liver characteristics were assessed retrospectively to identify those which would be considered high or low risk grafts as regards their susceptibility to IRI. The distinction between high- and low-risk livers was exclusively based on the reported risk factors and available data, and it cannot be established whether the low-risk livers would have functioned after transplantation. Finally, steatosis was assessed microscopically in haematoxylin and eosin (H&E)-stained wedge biopsies due
to the known discrepancy between gross and microscopic steatosis evaluation, as reported by our team [64] and others [65–68].

Mitochondrial assessment

Preservation groups. The Organ Recovery Workstation prototype, a modified version of the Lifeport Kidney Transporter machine with a dual pumping system (Organ Recovery Systems, Zaventem, Belgium), was used for end-ischaemic single-vessel HMP following the primary SCS period during liver transport. This prototype did not contain an oxygen delivery system, which was integrated for the second stage of the study, Fig 1. Consequently, experiments were performed in 2 stages with randomisation of donor organs between preservation methods at both stages, where each donor organ was utilised for only one preservation group as described previously [69]. Simple donor organ randomisation was performed using a computer-generated list of random numbers and the allocation sequence was concealed in numbered, opaque, and sealed envelopes. Formal sample size calculation was not performed but was guided by feasibility objectives and available resources in line with liver recruitment and anticipated numbers of research-approved livers during the study period.

Fig 1. Diagram of the organ recovery workstation, showing the installed membrane oxygenator and perfusate flow.

https://doi.org/10.1371/journal.pone.0257783.g001
A total of 38 livers were used for mitochondrial evaluation. Initially, 20 livers were randomly assigned to stage 1 into static cold storage (SCS, n = 6) as a control group, arterial perfusion through the hepatic artery (AP, n = 7), and non-oxygen supplemented venous perfusion through the portal vein (nOVP, n = 7). The SCS group represented continued SCS after the primary SCS period during liver transport, and these livers were submerged in 2 L of Kidney Preservation Solution-1 (KPS-1, Organ Recovery Systems, Zaventem, Belgium) and placed in the icebox for the equivalent period of 4 hours. Although KPS-1 is not usually used for SCS preservation, it was utilized herein to reduce the possible bias from using different preservation solutions. Arterial-only perfusion was assessed following an earlier study by our team, reporting similar endothelial preservation in single- and dual-vessel perfusion [70]. However, we acknowledge that single arterial perfusion is not an established route for clinical liver preservation using HMP.

In stage 2, 18 livers were randomly assigned to nOVP (n = 7) and oxygen supplemented portal vein perfusion (OVP, n = 11). The arterial perfusion group was omitted in this stage as the main focus was on oxygenated vs. air-equilibrated venous perfusion. Donor characteristics and perfusion settings for the nOVP groups in stages 1 and 2 of the study were similar.

End-ischaemic HMP. End-ischaemic single-vessel HMP was performed for 4 hours with 2 L of recirculating KPS-1 through the hepatic artery (HA) or portal vein (PV) at 30 mmHg or 7 mmHg, respectively. Perfusion settings were based on previous work by our team [69, 70] and others [71], which were adapted from clinical kidney HMP and resulted in homogenous graft perfusion. For the OVP group, 100% oxygen was administered to the perfusion circuit at a fixed rate of 0.5 L/min using a membrane oxygenator (Dideco Kids D100, Sorin Group Italia, Mirandola, Italy; perfusate pO₂, 735 mmHg). Hypothermia was maintained at 4–8°C, as per our previous studies [69, 70].

Sample collection and mitochondrial isolation. Wedge liver biopsies from segments IV and VII were obtained at the beginning and the end of end-ischaemic HMP or the 4-hour SCS in our laboratory, aiming for > 0.5 g/specimen [25]. As the optimal sampling regime is unknown, we selected these 2 sites and compared them as an indication of heterogeneity. Tissue specimens were immediately snap-frozen in liquid nitrogen and placed on ice until homogenisation (Eurostar digital homogeniser, IKA®—Werke GmbH & Co.KG, Staufen, Germany). Mitochondria were isolated by differential centrifugation according to Rickwood et al. [72] and the pellets were suspended in the homogenising buffer and stored at -80°C. Mitochondrial enzyme assays were performed within one week of specimen collection.

Spectrophotometric assessment of mitochondrial injury and function. Spectrophotometry assays were performed on mitochondrial fractions of frozen samples rather than fresh tissue due to logistic reasons, and this also precluded the use of polarography, which requires fresh samples [73, 74]. Protein concentrations were used to standardize the mitochondrial enzyme activities to the amount of tissue in the biopsy and were measured using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Massachusetts, USA). Citrate synthase was used to evaluate mitochondrial membrane integrity and mass [24, 75–78] and aconitase was used as a marker of irreversible ROS-mediated mitochondrial injury [79–81]. These 2 assays were performed according to Protasoni et al. [82] and Gardner et al. [79], respectively, and each specimen was assayed in quadruplicate. Mitochondrial function was studied by measuring electron transport chain (ETC) enzyme activities. Nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase (complex I), succinate cytochrome c reductase (complexes II & III), and cytochrome c oxidase (complex IV) assays were performed according to the methods of Ragan et al. [83], King et al. [84], and Protasoni et al. [82], respectively, and each specimen was assayed in triplicate.
Real-time assessment of parenchymal and perfusate oxygen

Separate to the mitochondrial assays above, an additional cohort of 6 sequential livers (non-randomised) were used to evaluate the delivery efficiency of oxygen during HMP. Fibre-optic oxygen microsensors (PreSens GmbH, Regensburg, Germany) continuously recorded oxygen concentrations in the perfusate and parenchyma using a flow-through sensor connected to the PV cannula and a needle-type sensor mounted in a 27-gauge diameter needle, respectively. Before each experiment, the microsensors were calibrated according to the manufacturer’s instructions and the $pO_2$ measurements were corrected for temperature and atmospheric pressure.

Standard perfusions were run for 3 hours using PV-only perfusion at 7 mmHg constant pressure. Parenchymal $pO_2$ was assessed at 2 representative sites (segments IV and VII) and the intra-liver variation was calculated. To obtain a stable baseline oxygen measurement in perfusate and parenchyma, end-ischaemic HMP was initially run for 30 minutes using air-equilibrated (room air) perfusate. Perfusate was then oxygenated with 100% oxygen at 0.5 L/min for 1.5 hours. After 2 hours of HMP (air-equilibrated and oxygenated perfusion), the oxygen was switched off whilst maintaining pump perfusion for another 1 hour to obtain the dynamics of oxygen depletion. The whole process was divided into 3 phases: baseline pre-oxygenation, active-oxygenation, and post-oxygenation perfusion.

Statistical analysis

Data were analysed using IBM SPSS Statistics for Macintosh (Version 20.0. Armonk, NY: IBM Corp) and presented as medians and interquartile ranges (IQR) for continuous variables or numbers and percentages for nominal variables. Non-parametric tests were used due to the small sample size and abnormal distribution. For continuous data, Kruskal-Wallis or Mann-Whitney tests were used to compare between groups, and Friedman or Wilcoxon tests were used for within-group comparisons. Categorical data were compared using Chi squared test. The level of significance was set at $p < 0.05$.

Results

Donor graft characteristics

Characteristics of the donor grafts are presented in Table 1. Reported causes of donor death included intracranial haemorrhage ($n = 29, 66\%$), hypoxia ($n = 10, 23\%$) and other causes including respiratory failure, infection, and trauma ($n = 5, 11\%$). The decision to decline grafts for transplantation was multifactorial; the most common reported factor was moderate to severe steatosis ($n = 22, 50\%$), followed by anatomical reasons ($n = 7, 16\%$), fibrosis ($n = 6, 14\%$), poor flow during on-table flush ($n = 6, 14\%$), long WIT ($n = 5, 11\%$), and other factors such as tumours, poor liver function tests, long intensive care stay, and long cold ischaemic time ($n = 4 each, 9\%$). Importantly, 3 livers (7\%) were declined due to the lack of a suitable recipient. Over a half (59\%) of research livers in this study were obtained from DCD donors, compared to 17\% of transplants from DCD donors over the same time period, indicating that non-proceeding donations were disproportionately higher for DCD compared with DBD donors [85]. There were no significant differences in donor graft variables between the preservation groups, Table 2.

Mitochondrial injury and function

Stage 1. The activities of citrate synthase, aconitase, and ETC enzymes I to IV were compared between SCS ($n = 6$), AP ($n = 7$), and nOVP ($n = 7$) livers. The change in mitochondrial
Krebs cycle and ETC enzyme functions were not significantly different after 4-hour end-ischaemic HMP compared with 4-hour SCS preservation (p > 0.05), Fig 2.

Table 1. Characteristics of donor liver grafts (n = 44).

| Donor characteristics            | SCS (n = 6) | AP (n = 7) | nOVP (n = 7) | Stage 1 (p value) | Inter-group difference |
|----------------------------------|------------|-----------|-------------|------------------|------------------------|
| Donor age (years)               | 58 (52–66) | 56 (51–65) | 57 (49–61)  | 0.28             | 0.28                   |
| Donor gender                     | 15 females (34%); 29 males (66%) | 18 DBD (41%); 26 DCD (59%) | 0.77          | 0.44             | 0.96                   |
| Donor weight (kg)                | 89 (70–95) | 89 (70–114) | 94 (83–114) | 0.36             | 0.36                   |
| Donor BMI                        | 29 (26–33) | 31 (25–37) | 31 (25–37)  | 0.68             | 0.68                   |
| ALT (IU/L)                       | 36 (19–72) | 52 (19–73) | 52 (19–73)  | 0.77             | 0.77                   |
| Bilirubin (umol/L)               | 11 (6–16)  | 11 (6–15)  | 11 (6–15)   | 0.28             | 0.28                   |
| UK DLI                           | 1.85 (1.31–2.15) | 1.85 (1.31–2.15) | 1.85 (1.31–2.15) | 0.76             | 0.76                   |
| ICU stay (days)                  | 3 (2–5)    | 3 (2–5)    | 3 (2–5)     | 0.43             | 0.43                   |
| CIT (hr)                         | 11.5 (11.0–12.3) | 11.5 (7.0–13.8) | 11.5 (7.0–13.8) | 0.65             | 0.65                   |
| Steatosis (%)                    | 2 (0–15)   | 6 (5–17)   | 6 (5–17)    | 0.31             | 0.31                   |
| F-WIT (min)                      | 18 (14–26) | 16 (15–30) | 17 (13–22)  | 0.82             | 0.82                   |

*a For the 26 DCD livers, functional warm ischaemic time (F-WIT) was calculated from the time of sustained drop in systolic blood pressure below 50 mmHg until cold in-situ flush [62].

*b Cold ischaemic time (CIT) was calculated from the time of cold in-situ flush until machine perfusion or the 4-hr static cold storage period in our laboratory. ALT, alanine transaminase; BMI, body mass index; DBD, donation after brain death; DCD, donation after cardiac death; ICU, intensive care unit; UK donor liver index (UK DLI) [63].

https://doi.org/10.1371/journal.pone.0257783.t001

Krebs cycle and ETC enzyme functions were not significantly different after 4-hour end-ischaemic HMP compared with 4-hour SCS preservation (p > 0.05), Fig 2.

Stage 2. The mitochondrial enzyme activities were compared between nOVP (n = 7), and OVP (n = 11) livers. The change in mitochondrial Krebs cycle and ETC enzyme functions were not significantly different between the 2 groups (p > 0.05), Fig 3.

Mitochondrial assessment in low-and high-risk livers. Out of 38 livers included in this part of the study, 8 livers were considered to have a low risk of IRI, Table 3. These livers were

Table 2. Comparison of donor liver characteristics between preservation groups.

| Characteristics            | Stage 1 | Stage 2 |
|----------------------------|---------|---------|
|                            | SCS (n = 6) | AP (n = 7) | nOVP (n = 7) | Inter-group difference (p value) | OVP (n = 11) | Inter-group difference (p value) |
| Age (years)                | 57 (50–70) | 56 (51–65) | 57 (49–61) | 0.28 | 62 (48–65) | 0.25 |
| Gender (male, %)           | 5, 71% | 7, 70% | 7, 87% | 0.77 | 6, 66% | 0.63 |
| Donor type (DCD, %)        | 4, 57% | 7, 70% | 6, 75% | 0.85 | 4, 44% | 0.96 |
| Donor weight (kg)          | 85 (70–90) | 87 (79–93) | 94 (83–114) | 0.36 | 90 (72–100) | 0.79 |
| Donor BMI                  | 27 (26–31) | 29 (26–35) | 31 (25–37) | 0.68 | 30 (25–32) | 0.79 |
| ALT (IU/L)                 | 20 (17–124) | 26 (19–46) | 52 (19–73) | 0.37 | 135 (36–304) | 0.21 |
| Bilirubin (umol/L)         | 6 (5–17) | 14 (6–21) | 11 (6–15) | 0.28 | 9 (6–13) | 0.36 |
| UK DLI                     | 1.47 (1.13–2.10) | 1.99 (1.42–2.33) | 1.85 (1.31–2.08) | 0.76 | 1.61 (1.04–2.12) | 0.79 |
| ICU stay (days)            | 3 (3–5) | 2 (2–5) | 3 (5–5) | 0.43 | 3 (3–5) | 0.08 |
| CIT (hr)                   | 11.5 (11.0–12.3) | 10.0 (9.8–14.3) | 11.5 (7.0–13.8) | 0.65 | 10.0 (10.0–14.0) | 0.16 |
| Steatosis %                | 2 (0–15) | 6 (5–17) | 2 (1–7) | 0.31 | 4 (0–19) | 0.36 |
| F-WIT (min)                | 18 (14–26) | 16 (15–30) | 17 (13–22) | 0.82 | 16 (12–26) | 0.86 |

*a Steatosis is expressed as the percentage of macrosteatosis in liver biopsies that were retrospectively examined by 2 pathologists at our institute. ALT, alanine transaminase; BMI, body mass index; CIT, cold ischaemic time; DCD, donation after cardiac death; F-WIT, functional warm ischaemic time of livers from donors after cardiac death in each group; UK-DLI, UK donor liver index.

https://doi.org/10.1371/journal.pone.0257783.t002
randomly allocated to the PV perfusion groups. In stage 1, 2 livers were allocated to the nOVP group. In stage 2, 1 liver was allocated to the nOVP group and 5 livers were allocated to the OVP group.

Post-preservation complex II-III activities were significantly lower in low-risk livers (73 nmol/mg/min (56–101) vs. 113 nmol/mg/min (89–160), p = 0.01). There was no significant difference in the remaining enzymes at any time point, including the initial pre-preservation (baseline) levels and the change in enzyme activities between low- and high-risk livers (p > 0.05), Table 4.

Mitochondrial intra-liver heterogeneity. The change in mitochondrial Krebs cycle and ETC enzyme functions before and after preservation were compared between segments IV and VII. There was no significant difference in any of the parameters studied (p > 0.05), Fig 4.

Fig 2. Box whisker plots of mitochondrial enzyme activities in stage 1. The plots demonstrate the distribution of enzyme activities round the median in each group, shown before and after 4-hr end-ischaemic hypothermic machine perfusion and 4-hr static cold storage. The change in enzyme activities was not significantly different between groups (p > 0.05). Top and bottom whiskers represent the maximum and minimum values, respectively. Circles represent outliers (1.5 to 3x interquartile range) and diamonds represent extreme outliers (> 3x interquartile range).

https://doi.org/10.1371/journal.pone.0257783.g002

Fig 3. Box whisker plots of mitochondrial enzyme activities in stage 2. The plots demonstrate the distribution of enzyme activities round the median in each group, shown before and after 4-hr end-ischaemic hypothermic machine perfusion. The change in enzyme activities was not significantly different between preservation groups (p > 0.05). Top and bottom whiskers represent the maximum and minimum values, respectively. Circles represent outliers (1.5 to 3x interquartile range) and diamonds represent extreme outliers (> 3x interquartile range).

https://doi.org/10.1371/journal.pone.0257783.g003
Perfusate and parenchymal oxygen concentrations

The parenchymal $pO_2$ was consistently lower than perfusate $pO_2$ in all 3 perfusion phases (baseline pre-oxygenation, active-oxygenation, and post-oxygenation perfusion, $p \leq 0.001$), Fig 5. Similar to parenchymal oxygen levels, perfusate oxygen concentrations increased significantly during oxygenated perfusion compared to pre-oxygenation and post-oxygenation phases ($p < 0.001$). Rising $pO_2$ levels in the parenchyma were detected within 5 minutes of starting active perfusate oxygenation. A steady state parenchymal $pO_2$ was achieved on average in 28 minutes compared to the perfusate, which stabilised within a few minutes (3 vs. 28 minutes, $p = 0.003$). The time required for $pO_2$ to return to baseline levels after cessation of active oxygenation was longer in the perfusate compared to the parenchyma (75 vs. 36 minutes, $p = 0.003$).

When intra-liver variation was assessed, $pO_2$ was lower in segment VII compared to segment IV during all 3 phases: pre-oxygenation, 0.6 mmHg (0.1–2.5) vs. 4.5 mmHg (0.2–6.4); active oxygenation, 179.9 mmHg (107.6–189.8) vs. 243.1 mmHg (149.9–312.8); post-oxygenation, 0.9 mmHg (0.2–2.8) vs. 4.8 mmHg (0.1–6.9). However, the difference was not statistically significant between the 2 liver segments ($p > 0.05$ for all 3 phases).

Discussion

This is the first study to analyse the activity of individual ETC and Krebs cycle enzymes and to report on parenchymal oxygen concentration during end-ischaemic HMP in the human liver.

---

Table 3. Reasons of graft decline for transplantation and characteristics of low-risk livers.

| Case | Reason 1            | Reason 2          | Reason 3                        | Other reasons a | Microscopic steatosis assessment b | Donor age | Donor gender | Donor weight (kg); BMI | ALT (IU/L) | Bilirubin (umol/L) | UK DLI | ICU stay (days) | F-WIT (min) |
|------|---------------------|-------------------|---------------------------------|-----------------|-----------------------------------|-----------|--------------|-----------------------|-------------|------------------|---------|----------------|-------------|
| 1    | Other               | Moderate steatosis | Research c                      | No suitable recipient | None                          | 61        | Male         | DBD 90; 29            | 74          | 16               | 1.12    | 4             | NA          |
| 2    | Anatomical          | Research c        | NR                              | No suitable recipient, subcapsular haematoma | Mild                        | 45        | Male         | DCD 99; 37            | 135         | 10               | 2.04    | 6             | 12          |
| 3    | Mild steatosis      | Research c        | NR                              | Mild steatosis, capsular laceration | Mild                        | 61        | Male         | DCD 90; 31            | 31          | 9                | 2.14    | 4             | 17          |
| 4    | Tumour              | Research c        | NR                              | Moderate steatosis | None                          | 58        | Female       | DBD 90; 33            | 60          | 13               | 1.19    | 2             | NA          |
| 5    | Other               | Research c        | NR                              | Mild steatosis   | None                          | 44        | Male         | DBD 94; 28            | 22          | 14               | 0.87    | 1             | NA          |
| 6    | Tumour              | NR                 | NR                              | Liver & kidneys lesions | None                        | 57        | Female       | DCD 55; 20            | 18          | 6                | 2.06    | 5             | 15          |
| 7    | Infection           | Moderate steatosis | Research c                      | Small bowel perforation | None                        | 52        | Female       | DCD 70; 27            | 72          | 4                | 2.09    | 6             | 11          |
| 8    | Moderate steatosis  | Research c        | NR                              | No suitable recipient | Mild                        | 81        | Male         | DBD 95; 28            | 36          | 16               | 1.24    | 1             | NA          |

These livers were identified retrospectively based on data collected from the NHSBT register, coordinators records, and HTA-A forms. Reasons 1, 2, 3 are the primary, secondary, and tertiary reasons for rejecting the liver as per the NHSBT register.

a Other reasons as obtained from HTA-A forms and liver coordinator records.
b Microscopic steatosis assessment was performed retrospectively on H&E-stained parenchymal sections by 2 pathologists at our institute. Steatosis was graded as normal (none), mild, moderate, and severe.
c Research, as a reason for graft decline, was recorded to keep track of the livers offered for research and was not a reason for declining grafts in itself; livers were only offered for research after being rejected for clinical use by all UK transplant centres. Cold ischaemic time was < 12 hours for low-risk livers (n = 8). ALT, alanine transaminase; DBD, donation after brain death; DCD, donation after cardiac death; F-WIT, functional warm ischaemic time; NA, not applicable; NR, not reported.

https://doi.org/10.1371/journal.pone.0257783
Oxidative damage to mitochondria is one of the main concerns with active oxygenation during HMP. Aconitase is a sensitive mitochondrial biomarker of irreversible oxidative injury by superoxide or hydrogen peroxide [79–81]. Based on our results, there was no evidence that highly-oxygenated perfusate caused more oxidative injury than air-equilibrated perfusion or SCS, as evidenced by similar aconitase measurements in all groups. Our results in human end-

Table 4. Mitochondrial enzyme activity in low- and high-risk livers.

| Enzyme activity     | Low-risk (n = 8) | High-risk (n = 30) | Intergroup difference (p-value) * |
|---------------------|-----------------|--------------------|----------------------------------|
|                     | Pre-preservation | Post-preservation  | Pre-preservation | Post-preservation  |
| Citrate synthase    | 134 (119–179)   | 134 (110–149)      | 141 (120–163) | 136 (113–171) | 0.74, 0.45, 0.31 |
| (nmol/mg/min)       |                 |                    |                    |                    |
| Aconitase           | 55 (47–66)      | 53 (43–73)         | 66 (47–90)      | 70 (45–86)      | 0.23, 0.33, 0.45 |
| (nmol/mg/min)       |                 |                    |                    |                    |
| Complex I activity  | 28 (21–40)      | 25 (21–33)         | 30 (21–45)      | 29 (21–41)      | 0.63, 0.37, 0.25 |
| (nmol/mg/min)       |                 |                    |                    |                    |
| Complex II-III activity | 106 (56–136) | 73 (56–101)        | 118 (93–196) | 113 (89–160) | 0.19, 0.01*, 0.17 |
| (nmol/mg/min)       |                 |                    |                    |                    |
| Complex IV activity | 9 (7–13)        | 8 (7–10)           | 9 (6–14)        | 9 (6–14)        | 0.90, 0.79, 0.54 |
| (k/mg/min)          |                 |                    |                    |                    |

Mitochondrial enzyme activities were measured before and after preservation (4-hr end-ischaemic HMP and 4-hr SCS) and compared between low- and high-risk livers.

* Intergroup difference, presented as p-value, was calculated for pre-preservation, post-preservation, and change in enzyme activities.

* denotes a significant intergroup difference.

https://doi.org/10.1371/journal.pone.0257783.t004

Fig 4. Box whisker plots of mitochondrial enzyme activities in liver segments IV and VII. The plots demonstrate the distribution of enzyme activities round the median in each segment, shown before and after 4-hr preservation. The enzyme activities were not significantly different between segments IV and VII (p > 0.05). The activities of citrate synthase, aconitase, complex I-III are expressed in nmol/mg/min while the activity of complex IV is expressed in k/mg/min. Top and bottom whiskers represent the maximum and minimum values, respectively. Circles represent outliers (1.5 to 3x interquartile range) and diamonds represent extreme outliers (> 3x interquartile range).

https://doi.org/10.1371/journal.pone.0257783.g004
ischaemic HMP are consistent with animal studies showing minimal oxidative damage during SCS or SCS followed by HMP, and more specifically, the lack of oxidative damage when high-oxygen flow is introduced into the perfusate [39, 86]. Additionally, mitochondrial mass and membrane integrity were preserved in all groups, as shown by stable mitochondrial citrate synthase activity [24, 75–78].

There was no significant change in isolated ETC enzyme activities over the time course of end-ischaemic perfusion as compared to SCS preservation, indicating stability of this part of mitochondrial respiration and confirming the lack of oxidative damage to respiratory chain enzymes. Mechanistic assessment of mitochondrial function during HOPE reported reduced mitochondrial respiration based on decreasing perfusate NADH and pCO$_2$ in a porcine model [35]. However, it was not demonstrated whether the decreased NADH concentration was due to increased oxidation (consumption) or decreased production. In addition, pCO$_2$ was reported to increase initially and was consistently higher than deoxygenated perfusion [35], indicating that mitochondrial respiration was activated, at least initially. Other experimental models show contradicting results of increased oxygen consumption and active mitochondrial respiration following oxygenated HMP [44–46].

The reason for the discrepancy in mitochondrial activity between previous experimental models and the current study is unclear but could be related to differences in endpoints, methodology, and species [87, 88]. Importantly, the current study is the only one to report on mechanistic changes in ETC enzymes during end-ischaemic HMP of human discard livers. The lack of interaction between mitochondria and cytosol in isolated mitochondrial assays could also be relevant in this study; mitochondrial complex I and possibly complex II undergo a conformational change between an active and inactive form depending on the cellular state and substrate availability, without affecting the abundance of the enzymes [89]. Recent evidence also indicates that complex I inactivation after reperfusion is associated with reversible dissociation of the flavin mononucleotide cofactor from complex I [90], suggesting that the enzyme activity can be maintained if suitable circumstances are provided. More mechanistic studies on
mitochondrial alterations during end-ischaemic HMP are required to enhance our understanding of the complex mitochondrial machinery in preserved organs.

The discrepancy in the mitochondrial results outlined above might indicate that other mechanisms are responsible for the proposed protective effect of end-ischaemic HMP. A possible mechanism of mitochondrial protection during end-ischaemic HMP could be related to a reversible and transient increase in mitochondrial respiration at the start of end-ischaemic HMP, leading to consumption (oxidation) of the reducing substances and stabilisation of the ETC enzymes with subsequent dampening of the inflammatory response. This hypothesis agrees with previous evidence indicating that mitochondrial inactivity and abundance of electrons from reducing substrates are the main triggers of the ROS burst via reverse electron transport, which is abolished in the presence of active mitochondria [20]. Mitochondrial assessment in the current study was restricted to 2 time points only which may not have adequately reflected real-time changes in mitochondrial activity. Future research should aim to measure mitochondrial function at more frequent intervals or in real-time.

There is a consensus that increased reverse activity of complex II during ischaemia with subsequent accumulation of succinate are necessary for the ROS burst associated with reperfusion [17, 20, 22]. Our results show greater post-perfusion complex II-III activity in high-risk marginal livers, which suggests that this group has a higher potential to generate ROS upon reperfusion. This finding has not been reported previously in the context of liver preservation, including end-ischaemic HMP. As such, a more detailed analysis of complex II activity and succinate levels could provide new biomarkers for graft viability assessment.

Another research area which should be explored for possible therapeutic interventions is methods to decrease succinate accumulation during ischaemia or succinate oxidation upon reperfusion. Recent studies in animal models of stroke and myocardial infarction have shown promising results for mitochondria-targeted therapy [17, 91–94]. HMP could allow mitochondrial manipulation during the critical time of ischaemic succinate accumulation, which provides a promising opportunity for protection against IRI. This could provide an advantage over normothermic machine perfusion which has not shown evidence of mitochondrial protection and is also associated with a variable degree of reperfusion injury [95].

The optimal number of specimens or biopsies required for accurate mitochondrial activity assessment during human liver preservation is unknown. Intra-liver heterogeneity was examined here in central (segment IV) and peripheral (segment VII) parenchymal sites, and there were no significant differences. This implies that the 2 specimens were representative of the whole liver and that one biopsy is adequate for spectrophotometric analysis of mitochondrial enzymes in future studies.

Parenchymal oxygen was lower in right lobe segment VII compared to central segment IV, but the difference was not significant, possibly due to type II error. This segmental variation in oxygen tensions has not been described previously during end-ischaemic HMP, and could be related to gradual oxygen consumption with perfusate moving distally or due to variation in hepatic blood flow between liver segments [96, 97], which was not directly assessed here. It is unlikely that the gradual decrease in oxygen concentration was associated with inadequate oxygen supply distally, based on similar mitochondrial function and injury between the 2 liver segments.

Parenchymal \( pO_2 \) was consistently lower than perfusate \( pO_2 \) during oxygenated and air-equilibrated perfusion, and parenchymal \( pO_2 \) dropped significantly faster after cessation of oxygen flow. It is unlikely that the lower parenchymal oxygen was due to poor organ perfusion, as these livers perfused homogenously on gross examination and perfusion dynamics improved throughout perfusion as described previously by our team [69]. Air-equilibrated perfusion in the absence of an oxygen carrier in the perfusate was associated with consumption
of almost all available oxygen, with a median parenchymal \( pO_2 < 5 \) mmHg in central and peripheral liver segments. This is a reflection of the large liver size and dense parenchyma in the human liver and active basal metabolism. Collectively, these results imply active metabolism and the necessity of oxygen during end-ischaemic HMP of the liver, in line with previous studies [35, 71, 98–101].

The parenchymal oxygen levels increased within 5 minutes of commencing active oxygenation, which agrees with experimental studies in the HOPE model that reported graft perfusion within 5 minutes of commencing perfusion with a fluorescein-stained perfusate [102]. Altogether, these findings indicate that end-ischaemic HMP is capable of delivering oxygenated perfusate to the tissues within a short perfusion time. Despite early oxygen diffusion to the parenchyma, there was a time lag on average of 28 minutes (range up to 44 minutes) between commencing active perfusate oxygenation and achieving stable parenchymal oxygen levels. This lag period suggests that oxygenated perfusion triggered initial mitochondrial respiration with increased oxygen consumption, as identified by the upward slope of parenchymal oxygen, which was followed by stabilisation of mitochondrial respiration producing the parenchymal oxygen plateau. These observations indicate the ability of mitochondria to respond to oxygen alterations in the medium by changing their respiratory function during hypothermia. Notably, the change in parenchymal oxygen was evident following the initiation of oxygen, but this does not rule out a lower baseline mitochondrial activity in the air-equilibrated medium, as shown by the lower parenchymal \( pO_2 \) compared to the perfusate.

This study presented a few limitations. First, the liver grafts studied had been declined for clinical transplantation and hence there is no information on how mitochondrial evaluation would have equated with post-transplant graft function. However, results from this research and other preclinical studies could provide essential information for refining diagnostic tools and can be implemented for designing future clinical protocols. Second, the study was not powered to assess efficacy of end-ischaemic HMP and a formal sample size calculation was not done. Steps were taken to improve the power and precision within the limits of the anticipated liver recruitment and study design, including the analysis of paired measurements of continuous variables and measuring the enzyme activity in triplicate or quadruplicate for each specimen. Third, the 4-hour preservation period after the primary SCS might have been insufficient to detect differences in ETC enzyme activities; functions of ETC complexes II, III, IV and mitochondrial respiration were maintained up to 24 hours in cold-stored rodent and pig livers [24, 25]. Fourth, more information on mitochondrial respiration could have been obtained by additional polarographic and adenine nucleotide assays in freshly isolated mitochondria or cells, but these tests were not performed due to logistic reasons. Future research should include these analyses in addition to measurement of mitochondrial electron donors and carriers. Newer methods of mitochondrial function assessment in intact cells using fluorescence microscopy could also prove valuable in this context [103]. Finally, an additional period of warm reperfusion could have been beneficial for examining the endpoints following warm reperfusion injury. However, isolated reperfusion would not provide data similar to the clinical scenario due to the absence of circulating leukocytes and platelets.

In summary, spectrophotometric evaluation of mitochondrial injury and function in end-ischaemic HMP of the human liver is feasible. We found preliminary evidence that actively oxygenated and air-equilibrated end-ischaemic HMP did not induce mitochondrial oxidative damage during the ischaemic period, and that mitochondrial respiratory chain complexes remained intact during cold preservation for 4 hours. Mitochondria likely respond to variable oxygen levels in the perfusate by adapting their respiratory function during end-ischaemic HMP. Besides, there was evidence of early oxygen diffusion and possible site variation in parenchymal oxygen levels. Measurement of complex II-III activities might identify
biomarkers for graft quality assessment and should be further investigated in perfused organs destined for clinical use in sufficiently-powered trials. Future research should aim to identify the optimal oxygen supply during end-ischaemic HMP of the human liver and to verify if certain marginal livers are better protected by oxygenated or air-equilibrated hypothermic perfusion. Addressing these questions will consequently affect the design of future organ perfusion systems and the outcome of liver transplantation. Finally, more studies are required to investigate novel mitochondria-targeted therapeutics.

Supporting information

S1 Data.
(XLSX)

Acknowledgments

We would like to thank the liver transplant coordinators for their great assistance in this research, and the NHSBT Statistics and Clinical Studies Department for providing donor data. We would also like to thank Dr Tu Vinh Luong and Dr Jennifer Watkins from the Department of Cellular Pathology, Royal Free London NHS Foundation Trust for microscopic evaluation and reporting of steatosis. The views expressed in this research are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Author Contributions

Conceptualization: Hamid Abudhaise, Peter DeMuylder, Barry Fuller, Brian R. Davidson.
Data curation: Hamid Abudhaise.
Formal analysis: Hamid Abudhaise.
Funding acquisition: Peter DeMuylder, Barry Fuller, Brian R. Davidson.
Investigation: Hamid Abudhaise.
Methodology: Hamid Abudhaise, Jan-Willem Taanman.
Resources: Peter DeMuylder.
Supervision: Jan-Willem Taanman, Barry Fuller, Brian R. Davidson.
Writing – original draft: Hamid Abudhaise.
Writing – review & editing: Hamid Abudhaise, Jan-Willem Taanman, Barry Fuller, Brian R. Davidson.

References

1. D’Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation. 1991; 51(1):157–63. Epub 1991/01/01. https://doi.org/10.1097/00007890-199101000-00024 PMID: 1987685.
2. Ploeg RJ, D’ALESSANDRO AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation. 1993; 55 (4):807–13. https://doi.org/10.1097/00007890-199304000-00024 PMID: 8475556.
3. Garcia CE, Bramhall S, Mirza DF. Use of marginal donors. Current opinion in organ transplantation. 2000; 5(2):50–6.
4. Callaghan CJ, Charman SC, Muiesan P, Powell JW, Gimson AE, van der Meulen JH. Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study. BMJ open. 2013; 3(9). https://doi.org/10.1136/bmjopen-2013-003287 PMID: 24002984

5. Verhoeven CJ, Farid WR, de Jonge J, Metselaar HJ, Kazemier G, van der Laan LJ. Biomarkers to assess graft quality during conventional and machine preservation in liver transplantation. Journal of hepatology. 2014; 61(3):672–84. https://doi.org/10.1016/j.jhep.2014.04.031 PMID: 24798816

6. Said RF. Current status of liver transplantation. Archives of Iranian medicine. 2012; 15(12):772–6. Epub 2012/12/04. 0121512/amir.0011. https://doi.org/0121512/amir.0011 PMID: 23199251.

7. Hameed AM, Hawthorne WJ, Pleass HC. Advances in organ preservation for transplantation. ANZ journal of surgery. 2017; 87(12):976–80. https://doi.org/10.1111/ans.13713 PMID: 27490874

8. Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review. Liver Transplantation. 2010; 16(9):1016–32. https://doi.org/10.1002/lt.22117 PMID: 20818739

9. Jay CL, Lyuksenburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Annals of surgery. 2011; 253(2):259–64. https://doi.org/10.1097/SLA.0b013e318204e658 PMID: 21245668

10. O’Neill S, Roebuck A, Khoo E, Wigmore SJ, Harrison EM. A meta-analysis and meta-regression of outcomes including biliary complications in donation after cardiac death liver transplantation. Transplant International. 2014; 27(1):1159–74. https://doi.org/10.1111/ti.12403 PMID: 25052036

11. Chan EY, Olson LC, Kiethard JA, Perkins JD, Bakthavatsalam R, Halldorson JB, et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver transplantation. 2008; 14(5):604–10. https://doi.org/10.1002/lt.21361 PMID: 18433032

12. Hessheimer AJ, Cárdenas A, García-Valdecasas JC, Fondevila C. Can we prevent ischemic-type biliary lesions in donation after circulatory determination of death liver transplantation? Liver Transplantation. 2016; 22(7):1025–33. https://doi.org/10.1002/lt.24460 PMID: 27082839

13. de Vries Y, von Meijenfeldt FA, Porte RJ. Post-transplant cholangiopathy: classification, pathogenesis, and preventive strategies. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2018; 1864(4):1507–15.

14. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annual review of genomics and human genetics. 2010; 11:25–44. https://doi.org/10.1146/annurev-genom-082509-141720 PMID: 20690818

15. van Golen RF, van Gulik TM, Heger M. Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. Free Radical Biology and Medicine. 2012; 52(8):1382–402. https://doi.org/10.1016/j.freeradbiomed.2012.01.013 PMID: 22326617

16. van Golen RF, van Gulik TM, Heger M. The sterile immune response during hepatic ischemia/reperfusion. Cytokine & growth factor reviews. 2012; 23(3):69–84. https://doi.org/10.1016/j.cytofgfr.2012.04.006 PMID: 22609105

17. Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014; 515(7527):431. https://doi.org/10.1038/nature13909 PMID: 25383517

18. Olthof PB, Reiniers MJ, Dirkes MC, van Gulik TM, Heger M, van Golen RF. Protective mechanisms of hypothermia in liver surgery and transplantation. Molecular Medicine. 2016; 22(7):1025–33. https://doi.org/10.1002/lt.24460 PMID: 27082839

19. Saito N, Tsukada H, Murata M, Hara M, Haraya M, Takahashi N, et al. Mitochondrial function and injury in liver HMP. Mitochondrial function and injury in liver HMP.
25. Kuznetsov AV, Strob D, Ruttmann E, Konigsrainer A, Margreiter R, Gnaiger E. Evaluation of mitochondrial respiratory function in small biopsies of liver. Analytical biochemistry. 2002; 305(2):186–94. https://doi.org/10.1006/abio.2002.5658 PMID: 12054447.

26. Roussin W. Mitochondrial complexes I, II, III, IV, and V in myocardial ischemia and autolysis. The American journal of physiology. 1983; 244(6):H743–8. Epub 1983/06/01. https://doi.org/10.1152/ajpheart.1983.244.6.H743 PMID: 6305212.

27. De Groot H, Littauer A, Noll T. Metabolic and pathological aspects of hypoxia in liver cells. Oxygen sensing in tissues: Springer; 1988. p. 49–64.

28. Guarrera JV, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010; 10(2):372–81. https://doi.org/10.1111/j.1600-6143.2009.02932.x PMID: 19958323.

29. Dutkowski P, Schlegel A, de Oliveira M, Mullhaup B, Neff F, Clavien PA. HOPE for human liver grafts obtained from donors after cardiac death. Journal of hepatology. 2014; 60(4):765–72. https://doi.org/10.1016/j.jhep.2013.11.023 PMID: 24295869.

30. Dutkowski P, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scaleria I, et al. First comparison of hypothermic oxygenated perfusion versus static cold storage of human donation after cardiac death liver transplants: an international-matched case analysis. Annals of surgery. 2015; 262(5):764–71. https://doi.org/10.1097/SLA.0000000000001473 PMID: 26583664.

31. Van Rijn R, Karimian N, Matton A, Burlage L, Westerkamp A, van den Berg A, et al. Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. British Journal of Surgery. 2017; 104(7):907–17.

32. Guarrera JV, Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, et al. Hypothermic machine preservation facilitates successful transplantation of “orphan” extended criteria donors livers. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015; 15(1):161–9. Epub 2014/12/19. https://doi.org/10.1111/ajt.12958 PMID: 25521639.

33. van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, et al. Hypothermic Machine Perfusion in Liver Transplantation—A Randomized Trial. New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2031532 PMID: 33626248.

34. Muller X, Marcon F, Sapisochin G, Marquez M, Dondero F, Rayar M, et al. Defining benchmarks in liver transplantation: a multicenter outcome analysis determining best achievable results. Annals of surgery. 2018; 267(3):419–25. https://doi.org/10.1097/SLA.0000000000002477 PMID: 28855508.

35. Schlegel A, Rougemont O, Graf R, Clavien PA, Dutkowski P. Protective mechanisms of end-ischemic cold machine perfusion in DCD liver grafts. Journal of hepatology. 2013; 58(2):278–86. https://doi.org/10.1016/j.jhep.2012.10.004 PMID: 23063573.

36. Schlegel A, Kron P, Graf R, Clavien P-A, Dutkowski P. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. Annals of surgery. 2014; 260(5):931–8. https://doi.org/10.1097/SLA.0000000000000941 PMID: 25243553.

37. Schlegel A, Graf R, Clavien PA, Dutkowski P. Hypothermic oxygenated perfusion (HOPE) protects from biliary injury in a rodent model of DCD liver transplantation. Journal of hepatology. 2013; 59 (5):984–91. https://doi.org/10.1016/j.jhep.2013.06.022 PMID: 23820408.

38. Kron P, Schlegel A, Mancina L, Clavien P-A, Dutkowski P. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans. Journal of hepatology. 2018; 68(1):82–91.

39. Dutkowski P, Graf R, Clavien PA. Rescue of the cold preserved rat liver by hypothermic oxygenated machine perfusion. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006; 6(5 Pt 1):303–12. https://doi.org/10.1111/j.1600-6143.2006.02126.x PMID: 16611326.

40. Dutkowski P, Furrer K, Tian Y, Graf R, Clavien PA. Novel short-term hypothermic oxygenated perfusion (HOPE) system prevents injury in rat liver graft from non-heart beating donor. Annals of surgery. 2006; 244(6):968–76; discussion 76–7. https://doi.org/10.1097/01.sla.0000247056.85590.6b PMID: 17122622; PubMed Central PMCID: PMC1856639.

41. Wyss RK, Méndez Carmona N, Arnold M, Segiser A, Mueller M, Dutkowski P, et al. Hypothermic, oxygenated perfusion (HOPE) provides cardioprotection via succinate oxidation prior to normothermic perfusion in a rat model of donation after circulatory death (DCD). American Journal of Transplantation. 2020.

42. I Hart NA, van der Plaats A, Faber A, Leuvenink HG, Olinga P, Wiersma-Buist J, et al. Oxigenation during hypothermic rat liver preservation: an in vitro slice study to demonstrate beneficial or toxic
57. Fuller B, Busza A, Proctor E. Possible resuscitation of liver function by hypothermic reperfusion in vitro.

56. Stegemann J, Minor T. Energy charge restoration, mitochondrial protection and reversal of preservation induced liver injury by hypothermic oxygenation prior to reperfusion. Cryobiology. 2009; 58(3):331–6. https://doi.org/10.1016/j.cryobiol.2009.03.003 PMID: 19318091.
59. Kim J-S, Boudjema K, D’Alessandro A, Southard J, editors. Machine perfusion of the liver: maintenance of mitochondrial function after 48-hour preservation. Transplantation proceedings; 1997: Elsevier.

60. Vekemans K, Liu Q, Brassil J, Komuta M, Pirenne J, Monbaliu D. Influence of flow and addition of oxygen during porcine liver hypothermic machine perfusion. Transplantation proceedings. 2007; 39 (8):2647–51. https://doi.org/10.1016/j.transproceed.2007.08.007 PMID: 17954199.

61. Rossaro L, Murase N, Caldwell C, Farghali H, Casavilla A, Starzl TE, et al. 31p-NMR spectroscopy of rat liver during simple storage or continuous hypothermic perfusion. The Journal of laboratory and clinical medicine. 1992; 120(4):559. PMID: 1402332

62. British Transplantation Society. Transplantation from deceased donors after circulatory death. July 2013.

63. Collett D, Friend PJ, Watson CJ. Factors Associated With Short- and Long-term Liver Graft Survival in the United Kingdom: Development of a UK Donor Liver Index. Transplantation. 2017; 101(4):786–92. Epub 2016/12/03. https://doi.org/10.1097/TP.0000000000001576 PMID: 27906826.

64. Abudhaise H, Luong TV, Watkins J, Fuller BJ, Davidson BR. Reliability and Accuracy of Clinical Assessment and Digital Image Analysis for Steatosis Evaluation in Discarded Human Livers. Transplantation proceedings. 2019; 51(6):1679–83. https://doi.org/10.1016/j.transproceed.2019.04.054 PMID: 31301860.

65. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Annals of surgery. 2009; 250(5):691–7. https://doi.org/10.1097/SLA.0b013e3181bcd6dd PMID: 19806055.

66. Hall AR, Dhillon AP, Green AC, Ferrell L, Crawford JM, Alves V, et al. Hepatic steatosis estimated microscopically versus digital image analysis. Liver international: official journal of the International Association for the Study of the Liver. 2013; 33(6):926–35. https://doi.org/10.1111/liv.12162 PMID: 23560780.

67. Levene AP, Kudo H, Armstrong MJ, Thursz MR, Gedroyc WM, Anstee QM, et al. Quantifying hepatic steatosis—more than meets the eye. Histopathology. 2012; 60(6):971–81. https://doi.org/10.1111/j.1365-2559.2012.04193.x PMID: 22372668.

68. Hall AR, Green AC, Luong TV, Burroughs AK, Wyatt J, Dhillon AP. The use of guideline images to improve histological estimation of hepatic steatosis. Liver International. 2014; 34(9):1414–27. https://doi.org/10.1111/lit.12612 PMID: 24905412.

69. Abudhaise H, Davidson B, DeMuylder P, Luong T, Fuller B. Evolution of dynamic, biochemical, and morphological parameters in hyperthermic machine perfusion of human livers: A proof-of-concept study. PloS one. 2018; 13(9):e0203803. https://doi.org/10.1371/journal.pone.0203803 PMID: 30216378.

70. Jomaa A, Gurusamy K, Siriwardana PN, Claworthy I, Collier S, de Muylder P, et al. Does hypothermic machine perfusion of human donor livers affect risks of sinusoidal endothelial injury and microbial infection? A feasibility study assessing flow parameters, sterility, and sinusoidal endothelial ultrastructure. Transplantation proceedings. 2013; 45(5):1677–83. Epub 2013/06/19. https://doi.org/10.1016/j.transproceed.2013.01.011 PMID: 23769023.

71. Monbaliu D, Vekemans K, De Vos R, Brassil J, Heedfeld V, Qiang L, et al. Hemodynamic, biochemical, and morphological characteristics during preservation of normal porcine livers by hypothermic machine perfusion. Transplantation proceedings. 2007; 39(8):2652–8. https://doi.org/10.1016/j.transproceed.2007.08.009 PMID: 17954200.

72. Rickwood D, Wilson M, Darley-Usmar V. Isolation and characteristics of intact mitochondria. Mitochondria-a practical approach. 1987:1–16.

73. Chretien D, Rustin P. Mitochondrial oxidative phosphorylation: pitfalls and tips in measuring and interpreting enzyme activities. Journal of inherited metabolic disease. 2003; 26(2–3):189–98. https://doi.org/10.1023/a:1024437201166 PMID: 12889660.

74. Spinazzi M, Casarin A, Pertegato V, Salvati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nature protocols. 2012; 7(6):1235–46. https://doi.org/10.1038/nprot.2012.058 PMID: 22653162.

75. Hood DA, Zak R, Pette D. Chronic stimulation of rat skeletal muscle induces coordinate increases in mitochondrial and nuclear mRNAs of cytochrome-c-oxidase subunits. The FEBS Journal. 1989; 179 (2):275–80. https://doi.org/10.1111/f.1432-1033.1989.tb14551.x PMID: 2537205.

76. Williams R, Salmons S, Newsholme E, Kaufman R, Mellor J. Regulation of nuclear and mitochondrial gene expression by contractile activity in skeletal muscle. Journal of Biological Chemistry. 1986; 261 (1):376–80. PMID: 3941082.
77. Holloszy J, Oscail L, Don I, Mole P. Mitochondrial citric acid cycle and related enzymes: adaptive response to exercise. Biochemical and biophysical research communications. 1970; 40(6):1368–73. https://doi.org/10.1016/0006-291x(70)90017-3 PMID: 4327015

78. Kuznetsov AV, Schneebeger S, Seiler R, Brandacher G, Mark W, Steurer W, et al. Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion. American Journal of Physiology-Heart and Circulatory Physiology. 2004; 286(5):H1633–H41. https://doi.org/10.1152/ajpheart.00701.2003 PMID: 14693685

79. Gardner PR, Nguyen DD, White CW. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. Proceedings of the National Academy of Sciences. 1994; 91(25):12248–52.

80. Tretter L, Ambus A. Measurement of ROS homeostasis in isolated mitochondria. Methods in enzymology. 547: Elsevier; 2014. p. 199–223. https://doi.org/10.1016/B978-0-12-801415-8.00012-6 PMID: 25416360

81. Flint DH, Tuminello J, Emptage M. The inactivation of Fe-S cluster containing hydro-lyases by superoxide. Journal of Biological Chemistry. 1993; 268(30):22369–76. PMID: 8226748

82. Protsasoni M, Kroon AM, Taanman J-W. Mitochondria as oncotarget: a comparison between the tetra-cycline analogs doxycycline and COL-3. Oncotarget. 2018; 9(73):33818. https://doi.org/10.18632/oncotarget.26107 PMID: 30333912

83. Ragan C, Wilson M, Darley-Ulsmar V, Lowe P. Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation. Mitochondria: a practical approach. 1987:79 –112.

84. King TE. [40] Preparations of succinate—cytochrome c reductase and the cytochrome b-c1 particle, and reconstitution of succinate-cytochrome c reductase. Methods in Enzymology. Volume 10: Academic Press; 1967. p. 216–25.

85. Transplant NBA. Annual report on liver transplantation 2019/2020 2020 [April 2021]. Available from: https://www.odt.nhs.uk/statistics-and-reports/organ-specific-reports/.

86. Dutkowski P, Krug A, Kryskiak M, Dünschede F, Seifert JK, Junginger T. Detection of mitochondrial permeability transition. Cardiovascular research. 2016; 109(3):374 –84. https://doi.org/10.1093/cvr/cvv279 PMID: 26705364

87. Ragan C, Wilson M, Darley-Ulsmar V, Lowe P. Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation. Mitochondria: a practical approach. 1987:79 –112.

88. Caraceni P, Gasbarrini A, Nussera A, Di Silvio M, Bartoli F, Borle AB, et al. Human hepatocytes are more resistant than rat hepatocytes to anoxia-reoxygenation injury. Hepatology. 1994; 20(5):1247 –54. Epub 1994/11/01. PMID: 7927259.

89. Stepanova A, Shurubor Y, Valsecchi F, Manfredi G, Galkin A. Differential susceptibility of mitochondrial electron chain carrier redox status by transhepatic light intensity during rat liver reperfusion. Cryobiology. 2003; 47(2):125–42. PMID: 12899454

90. Stepanova A, Susonov S, Niatsetskaya Z, Konrad C, Starkov AA, Manfredi G, et al. Redox-dependent loss of flavin by mitochondrial complex I in brain ischemia/reperfusion injury. Antioxidants & redox signaling. 2019; 31(9):608–22. https://doi.org/10.1089/ars.2018.7693 PMID: 31037949

91. Valls-Lacalle L, Barba I, Miró-Casas E, Alburquerque-Béjar JJ, Ruiz-Meana M, Fuertes-Agudo M, et al. Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition. Cardiovascular research. 2016; 109(3):374–84. https://doi.org/10.1093/cvr/cvv250 PMID: 27287543

92. Prag HA, Pala L, Kula-Alwar D, Mulvey JF, Loping D, Beach TE, et al. Ester prodrugs of malonate with enhanced intracellular delivery protect against cardiac ischemia-reperfusion injury in vivo. Cardiovascular Drugs and Therapy. 2020:1–13. https://doi.org/10.1007/s10557-020-07033-6 PMID: 32648168

93. Kuznetsov AV, Schneebeger S, Seiler R, Brandacher G, Mark W, Steurer W, et al. Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion. American Journal of Physiology-Heart and Circulatory Physiology. 2004; 286(5):H1633–H41. https://doi.org/10.1152/ajpheart.00701.2003 PMID: 14693685

94. Kohlhauer M, Pell V, Burger N, Spiroski A-M, Gruszczak A, Mulvey J, et al. Protection against cardiac ischemia-reperfusion injury by hypothermia and by inhibition of succinate accumulation and oxidation is additive. Basic research in cardiology. 2013; 114(3):18. https://doi.org/10.1007/s00395-013-0727-0 PMID: 23987396

95. Schiegel A, Kron P, Graf R, Dutkowski P, Clavien P-A. Warm vs. cold perfusion techniques to rescue rodent liver grafts. Journal of hepatology. 2014; 61(6):1267–75. https://doi.org/10.1016/j.jhep.2014.07.023 PMID: 25086285
96. Taniguchi H, Masuyama M, Koyama H, Oguro A, Takahashi T. Quantitative measurement of human tissue hepatic blood volume by C15O inhalation with positron-emission tomography. Liver. 1996; 16 (4):258–62. https://doi.org/10.1111/j.1600-0676.1996.tb00739.x PMID: 8877997

97. Taniguchi H, Oguro A, Takeuchi K, Miyata K, Takahashi T, Inaba T, et al. Difference in regional hepatic blood flow in liver segments—Non-invasive measurement of regional hepatic arterial and portal blood flow in human by positron emission tomography with H 2 15 O—. Annals of Nuclear Medicine. 1993; 7 (3):141–5. https://doi.org/10.1007/BF03164957 PMID: 8217488

98. Schiegel A, Dutkowski P. Role of hypothermic machine perfusion in liver transplantation. Transplant International. 2015; 28(6):677–89. https://doi.org/10.1111/tri.12354 PMID: 24852621

99. Monbaliu D, Liu Q, Libbrecht L, De Vos R, Vekemans K, Debbaut C, et al. Preserving the morphology and evaluating the quality of liver grafts by hypothermic machine perfusion: a proof-of-concept study using discarded human livers. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2012; 18(12):1495–507. https://doi.org/10.1002/lt.23550 PMID: 22987314.

100. van der Plaats A, Maathuis MH, NA TH, Bellekom AA, Hofker HS, van der Houwen EB, et al. The Groningen hypothermic liver perfusion pump: functional evaluation of a new machine perfusion system. Annals of biomedical engineering. 2006; 34(12):1924–34. https://doi.org/10.1007/s10439-006-9207-4 PMID: 17066322.

101. Luer B, Koetting M, Efferz P, Minor T. Role of oxygen during hypothermic machine perfusion preservation of the liver. Transplant international: official journal of the European Society for Organ Transplantation. 2010; 23(9):944–50. https://doi.org/10.1111/j.1432-2277.2010.01067.x PMID: 20210932.

102. Schiegel A, Kron P, De Oliveira ML, Clavien P-A, Dutkowski P. Is single portal vein approach sufficient for hypothermic machine perfusion of DCD liver grafts? Journal of hepatology. 2016; 64(1):239–41. https://doi.org/10.1016/j.jhep.2015.09.015 PMID: 26432884

103. Picard M, Taivassalo T, Gouspillou G, Hepple RT. Mitochondria: isolation, structure and function. The Journal of physiology. 2011; 589(18):4413–21. https://doi.org/10.1113/jphysiol.2011.212712 PMID: 21708903